Annual Report FY26 filed; AGM set for 29 September 2026
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krebs Biochemicals filed its 34th Annual Report for FY ended 31 March 2026. Total income fell to Rs 25.76 crores from Rs 44.02 crores, a 41% decline. Loss after tax narrowed to Rs 16.93 crores from Rs 26.94 crores. Net worth remains deeply negative at minus Rs 162.75 crores. Management admits the company has been incurring cash losses for years with no working capital and depends on promoter Ipca Labs (49.65% holder) for survival. 34th AGM on 29 September.
Persistent losses, deeply negative net worth, and revenue decline flag serious going concern risk; shareholders will vote on promoter RPT up to Rs 120 crores at AGM.